drugset
drugset / Trial / NCT01236352

Multiple Ascending Dose of BMS-911543

NCT01236352 ↗

Phase 1/2 Terminated 98 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum Tolerated Dose or at a Clinically Active Dose, and to determine if BMS-911543 will demonstrate efficacy in symptomatic myelofibrosis.

Timeline

Start
2011-04-07
Primary completion
2015-11-19
Completion
2015-11-19

Outcome

Outcome not reported

Stopped (Business): “Due to portfolio/business decisions by the sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-911543 Small molecule 5 mg Oral
Subject BMS-911543 Small molecule 10 mg Oral
Subject BMS-911543 Small molecule 20 mg Oral
Subject BMS-911543 Small molecule 40 mg Oral
Subject BMS-911543 Small molecule 80 mg Oral
Subject BMS-911543 Small molecule 120 mg Oral
Subject BMS-911543 Small molecule 160 mg Oral
Subject BMS-911543 Small molecule 200 mg Oral
Subject BMS-911543 Small molecule 240 mg Oral
Subject BMS-911543 Small molecule 320 mg Oral

Indications

cancer